CDI(US:CODX)2025-11-05 17:00Summary of Co-Diagnostics Fireside Chat - November 05, 2025 Company Overview - Company: Co-Diagnostics (NasdaqCM:CODX) - Industry: Molecular Diagnostics - Technology: Develops, manufactures, and markets advanced diagnostics technologies that are accurate, affordable, fast, easy to use, and non-invasive [3][6] Key Announcements - Joint Venture in Saudi Arabia: Recently announced, aimed at expanding market presence in a large, underserved market [1][19] - Artificial Intelligence Initiatives: New business unit focused on AI to enhance diagnostic capabilities [1][25] Core Technology and Products - Co-Primers Technology: Enables multiplex testing for multiple indications simultaneously, such as the forthcoming ABCR test for flu A, flu B, COVID-19, and RSV [7][8] - CODIAX PCR Pro: A miniaturized PCR device designed to be accessible and affordable, targeting large diagnostic gaps in markets like India and Saudi Arabia [10][11] - Clinical Trials: Upcoming trials for ABCR, human papillomavirus, and tuberculosis tests [11][39] Market Strategy - Focus on Emerging Markets: Significant infrastructure established in India with 15 tests currently sold; plans to leverage joint ventures in Saudi Arabia and India for growth [18][19] - U.S. Market Dynamics: Different regulatory pathways for tests; initial focus on point-of-care markets such as pharmacies and clinics [22][23] Financial Insights - Cost-Effective Solutions: The CODIAX PCR device priced between $300 to $500, significantly lower than competitors' devices costing $10,000 to $20,000 [33][34] - Margin Profile: Anticipated margins of approximately 30% on instruments and 70% to 80% on consumables [37][38] Future Milestones - Clinical Trials: Introduction of tests into clinical trials in the U.S., India, and Africa [39] - SPAC Transaction for Cosara: Plans to pursue a SPAC transaction to capitalize on the infrastructure built in India [29][31] Investment Opportunities and Risks - Undervalued Stock: Company believes its stock is undervalued due to market misinterpretation of its ongoing COVID-related initiatives [41][42] - Sustainable Business Model: Focus on providing affordable diagnostics with ongoing revenue from consumables [42] Additional Insights - AI Integration: Ongoing development of AI models to enhance diagnostic accuracy and operational efficiency [26][28] - Global Health Impact: Commitment to improving healthcare access and quality, particularly in underserved regions [44] This summary encapsulates the key points discussed during the fireside chat, highlighting the company's strategic direction, technological advancements, and market opportunities.